Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Bode

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Diabetes Technology & Therapeutics|May 1, 2004
Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring systemBruce Bode, Kenneth Gross, Nancy Rikalo, et al.
Diabetes Technology & Therapeutics|May 27, 2020
Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring SubstudyMaciej T Malecki, Dachuang Cao, Rong Liu, et al.
Diabetes Care|January 29, 2005
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogsPhilip Raskin, Elsie Allen, Priscilla Hollander, et al.
Diabetes Care|August 11, 2016
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized TrialChantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 18, 2010
A valuation of infusion therapy to preserve islet function in type 1 diabetesAndrew Lloyd, Paul Swinburn, Kristina S Boye, et al.
Diabetes, Obesity & Metabolism|April 18, 2019
Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoringJeremy Pettus, Jasvinder Gill, Sachin Paranjape, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trialsBernard Zinman, J Hans DeVries, Bruce Bode, et al.
Journal of Medical Economics|June 14, 2016
Economic impact of hypoglycemia among insulin-treated patients with diabetesMatthew Sussman, Joseph A Sierra, Satish Garg, et al.
Mayo Clinic Proceedings|December 15, 2004
Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trialRobert Tanenberg, Bruce Bode, Wendy Lane, et al.
BMC Endocrine Disorders|April 19, 2014
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesAlan Sinclair, Bruce Bode, Stewart Harris, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Diabetes Technology & Therapeutics|May 1, 2004
Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring systemBruce Bode, Kenneth Gross, Nancy Rikalo, et al.
Diabetes Technology & Therapeutics|May 27, 2020
Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring SubstudyMaciej T Malecki, Dachuang Cao, Rong Liu, et al.
Diabetes Care|January 29, 2005
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogsPhilip Raskin, Elsie Allen, Priscilla Hollander, et al.
Diabetes Care|August 11, 2016
Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized TrialChantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 18, 2010
A valuation of infusion therapy to preserve islet function in type 1 diabetesAndrew Lloyd, Paul Swinburn, Kristina S Boye, et al.
Diabetes, Obesity & Metabolism|April 18, 2019
Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoringJeremy Pettus, Jasvinder Gill, Sachin Paranjape, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trialsBernard Zinman, J Hans DeVries, Bruce Bode, et al.
Journal of Medical Economics|June 14, 2016
Economic impact of hypoglycemia among insulin-treated patients with diabetesMatthew Sussman, Joseph A Sierra, Satish Garg, et al.
Mayo Clinic Proceedings|December 15, 2004
Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trialRobert Tanenberg, Bruce Bode, Wendy Lane, et al.
BMC Endocrine Disorders|April 19, 2014
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesAlan Sinclair, Bruce Bode, Stewart Harris, et al.
Pageof 7